naa a22 4500 510764401 CHVBK 20180411083151.0 cr unu---uuuuu 180411e20130201xx s 000 0 eng 10.1007/s12094-012-0893-0 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0893-0 Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma [Elektronische Daten] [Angeles Rovirosa, Izaskun Valduvieco, Carlos Ascaso, Antonio Herreros, Carlos Bautista, Ingrid Romera, Meritxell Arenas, Jaume Pahisa, Albert Biete] Purpose: To analyze the results of daily high-dose-rate brachytherapy (HDRBT) on local control and toxicity in the postoperative treatment of endometrial carcinoma (EC). Materials and methods: From January 2007 to September 2010, 112 patients were treated with HDRBT after surgery for EC. FIGO staging: 24-IA, 48-IB, 14-II, 12-IIIA, 2-IIIB, 8-IIIC1 and 4-IIIC2. Pathology 99/112 endometrioid and 23/112 other types. Radiotherapy patients were divided into two groups—Group 1 (70/112) consists of external beam irradiation (EBI) plus HDRBT (2 fractions of 5-6Gy) and Group 2 (42/112) consists of HDRBT alone (4 fractions of 5-6Gy). Toxicity evaluation RTOG scores for bladder and rectum, and the objective criteria of LENT-SOMA for vagina. Statistics bivariate analysis of Chi-square and Fisher exact tests. Results: With a mean follow-up of 29.52months (range 9.60-53.57) no patient developed vaginal-cuff relapse. In Group 1 early toxicity appeared in 9% in rectum, 8.5% in bladder (G1-G2) and 1.4% in vagina (G1); late toxicity was present in 8.5% in rectum (all G1-G2 but 1 G3) and in 25% in vagina (all G1-G2 but one G4). In Group 2, 9.4% developed G1-G2 bladder and 6.9% acute vagina (G1-G2) toxicity. Only 2.3% had a G1 rectal score and 6.9% had G1-G2 as vaginal scores for late problems. Conclusions: (1) Daily HDRBT using two fractions of 5-6Gy after EBI and four fractions of 5-6Gy as exclusive treatment was a safe regime. (2) Group 1 showed a higher incidence of late vaginal toxicity. Federación de Sociedades Españolas de Oncología (FESEO), 2012 High-dose-rate brachytherapy nationallicence Endometrial carcinoma nationallicence Rovirosa Angeles Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut Valduvieco Izaskun Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut Ascaso Carlos Public Health Department, University of Barcelona, IDIBAPS, Barcelona, Spain aut Herreros Antonio Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut Bautista Carlos Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut Romera Ingrid Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut Arenas Meritxell Medical Oncology Department, Hospital General de Reus, Tarragona, Spain aut Pahisa Jaume Gynecological Cancer Unit, Gynecology and Obstetrics Department, Hospital Clinic, Barcelona, Spain aut Biete Albert Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 111-116 1699-048X 15:2<111 2013 15 12094 https://doi.org/10.1007/s12094-012-0893-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0893-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rovirosa Angeles Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut NATIONALLICENCE 700 1- Valduvieco Izaskun Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut NATIONALLICENCE 700 1- Ascaso Carlos Public Health Department, University of Barcelona, IDIBAPS, Barcelona, Spain aut NATIONALLICENCE 700 1- Herreros Antonio Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut NATIONALLICENCE 700 1- Bautista Carlos Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut NATIONALLICENCE 700 1- Romera Ingrid Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut NATIONALLICENCE 700 1- Arenas Meritxell Medical Oncology Department, Hospital General de Reus, Tarragona, Spain aut NATIONALLICENCE 700 1- Pahisa Jaume Gynecological Cancer Unit, Gynecology and Obstetrics Department, Hospital Clinic, Barcelona, Spain aut NATIONALLICENCE 700 1- Biete Albert Gynecological Cancer Unit, Radiation Oncology Department, ICMHO, Hospital Clinic, University of Barcelona, IDIBAPS, C/Villarroel 170, 08036, Barcelona, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 111-116 1699-048X 15:2<111 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer